Lexicon Pharmaceuticals posts Q2 net loss

Lexicon Pharmaceuticals

06/08/2026 12:52

Overview
US biopharmaceutical firm's Q2 revenue fell sharply yr/yr
Company posted Q2 net loss after higher research costs for SONATA-HCM trial
Cash and investments rose after February stock sale and new Hercules Capital loan facility

Result Drivers
SONATA-HCM TRIAL COSTS - Higher external research expenses for ongoing Phase 3 SONATA-HCM trial drove up R&D costs
HIGHER SG&A COSTS - Selling, general and administrative expenses rose due to increased professional and consulting costs

Company press release: ID:nGNXb5k8CC

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$680,000
 
Q2 Loss Per Share
 
$0.07
 
Q2 Net Loss
 
$31.78 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.10, about 26.5% above its August 5 closing price of $2.45

Reuters Recommended Reads
Aug 5 - Arcus Biosciences Q2 revenue falls sharply on lower license income
Aug 5 - EyePoint Pharmaceuticals Q2 revenue drops on lower license income
Aug 3 - Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)